Obese survivors more often had hypogonadism, had received testicular irradiation, and needed testosterone replacement therapy compared to nonobese survivors. Conclusion: At young adulthood, long-term male ALL survivors have significantly increased body adiposity despite normal weight and BMI. Potential indicators of increased adiposity included high leptin and low SHBG levels. Serum testicular endocrine markers did not correlate with body adiposity.
Introduction
Long-term survivors of childhood acute lymphoblastic leukemia (ALL) have an increased prevalence of obesity [1, 2] and physical inactivity [3, 4] as well as a significantly elevated risk for cardiovascular disease [5, 6] and related mortality [7] in the years after treatment. In particular, abdominal obesity, which is known to be a risk factor for diabetes and cardiovascular diseases, has shown increased prevalence among ALL survivors [8] . Cranial radiotherapy (CRT) during ALL treatment has been implicated as a potential cause for excess weight gain among survivors [9, 10] . Although the mechanism by which CRT leads to obesity is unknown, hypothalamic damage leading to growth hormone deficiency or leptin insensitivity, or both, have been suggested as causative factors [9, 11] . Zhang et al. [12] in their current meta-analysis found a high obesity rate among pediatric ALL survivors regardless of the treatment received. Although survivors who received CRT had a slightly higher BMI z-score than survivors who received chemotherapy alone, the difference was small, and nearly half of the studies did not support a difference in obesity rate after CRT treatment. In particular, for ALL survivors treated under modern protocols that do not involve CRT, a high prevalence of obesity was also observed. These results suggest that ALL survivors have an elevated risk of being overweight/obese regardless of CRT treatment.
Emerging evidence links testosterone deficiency to multiple cardiovascular risk factors including obesity, diabetes, hypertension, and altered lipid profiles, suggesting that gonadal function plays an important role in the regulation of metabolic homeostasis [13] . A low serum total testosterone level predicts the development of central obesity and the accumulation of intra-abdominal fat [14, 15] . Similarly, low total and free testosterone as well as sex hormone-binding globulin (SHBG) levels are associated with an increased risk of developing metabolic syndrome, independent of age and obesity [16, 17] .
The purpose of this study was to evaluate long-term effects of childhood ALL on body composition among adult male survivors. We specifically aimed to assess the role of gonadal dysfunction in the development of adiposity and to identify treatment-related risk factors predisposing to obesity among adult male survivors of childhood cancer.
Patients and Methods

Study Population
Adult male long-term (>10 years) ALL survivors who were born in 1980 or earlier and had been treated at the Children's Hospital, Helsinki University Central Hospital, in 1970-1998 were identified through hospital records and invited to participate in a study assessing reproductive and bone health, related parameters as well as overall wellbeing, and marital, educational and employment status at adult age, as described earlier [18] [19] [20] . Of the total patient population (n = 164), 75 male long-term survivors were identified and contacted. Altogether, 51 subjects (68%) consented and 24 did not respond to the invitation. All the study patients and control persons were Caucasians. Based on hospital records, the clinical characteristics of the 24 nonparticipants were comparable with those of the participants (data not shown). Control subjects (56 healthy males with no history of malignancy, aged between 24 and 36 years) matched by age and ethnic background were recruited from occupational health services of Helsinki municipality area and Helsinki University Central Hospital. The Research Ethics Committee of Helsinki University Hospital approved the study; an informed written consent was obtained from all study subjects.
Study Protocol
The present study cohort comprised 49 ALL survivors and 55 controls who were clinically assessed, had available blood measurements relevant to testicular function, and body composition measured with dual-energy X-ray absorptiometry (DXA). A detailed history of the present health, physical exercise (number of active training sessions per week and daily hours of watching TV and videos), and ongoing endocrine replacement therapies and other medications was obtained by patient interview. Heights and weights were measured, and values were compared with the Finnish norms. The BMI was calculated as weight in kilograms divided by the square of height in meters (kg/m 2 ). BMI data were available for 48 ALL survivors and 53 controls.
Clinical Characteristics
Data on the ALL survivors' previous medical history included a diagnosis of growth hormone deficiency, hypothyroidism, or hypogonadism, cumulative doses of irradiation and cytotoxic drugs as well as pubertal development including Tanner stages, and height and weight. Hypogonadism was defined as a testosterone level <7 nmol/l.
Fat and Lean Mass
Measurements by DXA DXA (Hologic ® Discovery A, software version 12.3: 3; Bedford, Mass., USA) was used. Body and trunk fat mass (kg), body and trunk lean mass, and percentage of body and trunk fat were measured.
Biochemistry
Blood samples were collected between 8 and 10 a.m. Samples were centrifuged, and serum levels of follicle-stimulating hormone (FSH), luteinizing hormone, inhibin B, estradiol, testosterone, SHBG, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP3), and leptin were measured in the laboratory of Helsinki University Central Hospital [18] . The serum free testosterone level was calculated from a previously validated equation [21] . Serum osteocalcin and carboxylated osteocalcin, potential bone-derived regulators of energy metabolism [22] , and testosterone [23] were determined as previously described using a two-site immunoassay [24] . Serum adiponectin levels were determined with Quantikine Human Adiponectin Immunoassay (R&D Systems, Minneapolis, Minn., USA).
Statistical Analysis
Simple regression analysis, Student's unpaired t test (normally distributed variables), the Mann-Whitney U test (non-normally distributed variables), and the χ 2 test were used for statistical analysis (SPSS Statistics), as appropriate, to determine the relationship between whole body and trunk fat mass, whole body and trunk lean mass, percentages of whole body and trunk fat mass, and specified clinical variables, and to analyze differences in these parameters between subgroups. Since there was a significant difference in height between the groups and an interaction between height and parameters of body composition, comparisons were adjusted for height. A p value <0.05 was considered statistically significant. 
Results
Patient Characteristics
The 49 male ALL survivors were assessed at a median age of 29 years (range 25-38). Their median age at ALL diagnosis was 5 years. The median follow-up since the end of ALL therapy was 20 years (range 10-29; table 1 ). Seventy-three percent of the survivors had received CRT, 35% testicular irradiation, and 49% cyclophosphamide as part of their ALL treatment regimen. Hypogonadism had been diagnosed in 20 ALL survivors (41%); 16 of them (80%) had received testicular irradiation, 19 (95%) CRT, and 10 (50%) cyclophosphamide. At the time of assessment, 14 of the hypogonadal survivors had adequate substitution with testosterone while 6 (30%) had serum testosterone levels <7 nmol/l and were regarded as noncompliant to testosterone replacement therapy. None of the ALL survivors or controls were receiving growth hormone or thyroid hormone therapy at the time of the study or had been earlier diagnosed to have growth hormone deficiency or hypothyroidism. The median age of the 55 male controls was 30 years (range [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . The ALL survivors were significantly shorter that the controls (median 176.0 vs. 180. No difference in the number of overweight subjects (BMI ≥ 25) between ALL survivors and controls were detected. Seven of 48 (15%) ALL survivors and 5 of the 53 (9%) controls were obese (BMI ≥ 30; p = 0.42). Of these 7 obese survivors, 4 (57%) had received testicular irradiation, 6 (86%) CRT, and 3 (43%) were using testosterone substitution, while the corresponding numbers among the 41 nonobese ALL survivors were 13 (32%; p = 0.19), 23 (56%; p = 0.48), and 12 (29%; p = 0.47).
Biochemistry
There were significant differences between the ALL survivors and the male controls in hormonal parameters and testicular function, as reported previously [18] . The ALL survivors had significantly higher FSH levels, lower testosterone levels, and lower inhibin B levels but there was no difference in SHBG levels when compared to controls ( table 3 ) . The serum testosterone level was <7.0 nmol/l in 6 and 7-9 nmol/l in 4 ALL survivors while none of the controls had values <7.0 nmol/l and 2 had values of 7-9 nmol/l. Serum IGF-1 levels were similar, but IGFBP3 levels were lower in the ALL survivors (p < 0.001).
Serum leptin levels were higher (p = 0.012) in the ALL survivors than in the controls ( table 3 ) . Similarly, significantly higher levels of serum adiponectin were observed among ALL survivors (p = 0.003) while no difference in the levels of serum osteocalcin and carboxylated osteocalcin were detected between the groups ( table 3 ) . No correlations between serum testosterone and serum adiponectin or serum leptin levels were detected between ALL survivors and controls.
Survivors with a BMI ≥ 30 were more severely obese when compared with the obese controls. Their mean body fat mass was 33 kg and the mean trunk fat mass 16 kg as compared with 23 and 12 kg, respectively ( table 4 ) . Serum testosterone and SHBG levels were significantly lower among obese survivors when compared with nonobese survivors ( table 4 ) . This difference was not seen in the control group. Both obese survivors and controls displayed significantly higher serum leptin levels when compared with nonobese survivors and controls, respectively ( table 4 ) .
DXA Findings
The body composition findings are presented in table 2 . The ALL survivors had significantly lower trunk lean mass (p = 0.002) and body lean mass (p = 0.003), and higher percentages of trunk fat mass (p = 0.009) and body fat mass (p = 0.004). The differences between the groups remained significant even when adjusted for height ( table 2 ).
The BMI correlated significantly (p < 0.001) with all DXA parameters including body fat (r = 0.93), trunk fat (r = 0.93), percent body fat (r = 0.83), percent trunk fat (r = 0.87), and trunk lean (r = 0.68) and body lean (r = 0.72) mass ( table 5 ) . In survivors and controls, SHBG as- ( table 5 ) . No correlation between DXA parameters and age at the onset of leukemia or the time elapsed from the leukemia therapy was detected. When the group of ALL survivors was divided according to treatment-related parameters, no differences in serum leptin, adiponectin or osteocalcin levels, BMI, trunk fat mass, or lean mass parameters were observed between survivors who had received CRT and those without CRT, or between survivors who had received gonadotoxic doses of cyclophosphamide (>20 g/m 2 ) or testicular irradiation and those without such therapy. No associations with serum testosterone levels were detected for these parameters.
Discussion
We carried out a cross-sectional study to evaluate body composition parameters using DXA and their clinical and biochemical determinants in long-term male ALL survivors at young adult age (25-38 years) on average 20 years after the end of ALL therapy. The 49 ALL survivors had significantly higher percent fat mass at all measured sites than the 55 male controls without a history of cancer. There was no difference between body fat and trunk fat mass, which is possibly associated with the smaller size of the ALL survivors. The median heights of ALL survivors were lower, but their median weight and BMI values were not different from controls. Present observations support that the estimation of body adiposity among male ALL long-term survivors needs to be determined by other methods than by weight and BMI. The DXA-derived percentage of body fat was shown to more accurately reflect true body adiposity, supporting the earlier observation of Blijdorp et al. [25] .
ALL survivors had lower IGFBP3 levels, but their IGF-1 levels were similar to the controls. This may reflect the inferior growth hormone status in the ALL survivors. We found no correlation between absolute body fat mass and IGF-1. Instead, body and trunk lean mass was lower among ALL survivors and correlated significantly with serum IGF levels in the control group. This is in line with previous observations showing that an inferior growth hormone status affects body composition by decreasing lean body mass [10] .
We observed increased levels of leptin in male ALL survivors, in line with the observed increased adiposity. Previously increased leptin levels have been demonstrated among female survivors treated with and without CRT [26, 27] and, to a lesser extent, in male ALL survivors with CRT [28] . Serum leptin levels are known to increase soon 113 after ALL diagnosis [29] and remain high during the first year after chemotherapy withdrawal [11] . The present observation confirms long-term persistence of hyperleptinemia in male ALL survivors [28] . Normally, leptin acts by decreasing appetite and food intake which leads to a decrease in BMI. Obese individuals exhibit high levels of leptin expression in adipose tissue and have elevated circulating leptin levels which fail to reduce excess adiposity [30] . In the present study, very high levels of leptin were observed among obese ALL survivors, and even more remarkable increases in leptin levels were observed when the values were adjusted for the BMI. It has been shown that hypogonadal men have increased leptin levels and that testosterone substitution therapy can normalize elevated serum leptin levels [31] . The mechanisms by which testosterone reduces leptin levels are uncertain but may include the capacity of testosterone to reduce adipose tissue mass [32] . In the present study, no correlation between serum levels of testosterone and leptin or BMI was shown. Serum levels of adiponectin were higher in the survivors than in the controls. Adiponectin is known to inversely correlate with body fat [33] . In this study, no association between adiponectin, body fat mass, body lean mass, or percent body fat was observed. If adjusted for BMI, adiponectin levels showed an even more remarkable difference between survivors and controls. Earlier studies have not found differences in the levels of adiponectin between ALL survivors and controls. These high adiponectin levels in male survivors with increased percent body fat are contradictory to the known role of adiponectin as a factor that increases insulin sensitivity and decreases fat mass [33] . Previous studies indicate that serum concentrations of adiponectin in hypogonadal men, including those with Klinefelter syndrome, are higher than those in eugonadal men, and a significant reduction is observed after testosterone replacement therapy [34] . On the other hand, similar to our findings, some previous studies found no correlation between testosterone and adiponectin [35, 36] . The increased level of serum adiponectin among ALL survivors may reflect the partial Leydig cell insufficiency. A significant part of the presently studied survivors had received cancer treatments that potentially damage Leydig cells. The significance of adiponectin for body composition among adult male leukemia survivors remains unclear and needs to be evaluated in further studies.
A low serum testosterone level is known to be a significant risk factor for adiposity [13] [14] [15] . Therefore, it is important to ensure proper testosterone replacement therapy and follow the compliance in adult ALL survivors with testosterone deficiency. In the present cohort, altogether 20 of the ALL males had been diagnosed with hypogonadism during puberty. Most of them were on sufficient testosterone replacement therapy at the study visit, but 6 males (12% of the cohort) had untreated hypogonadism with a low testosterone concentration and increased gonadotrophin values. Despite a substantial number of hypogonadal survivors, we were not able to detect any correlation between the serum testicular endocrine markers testosterone, FSH, or inhibin B and any of the DXA-derived body composition parameters among ALL men. Instead, low serum SHBG levels associated significantly with increased body fat mass and percent body fat in both survivors and controls, in line with the suggested independent role of serum SHBG concentration as an indicator of metabolic syndrome, including central adiposity [37] . Severe obesity (BMI ≥ 30) but not overweight (BMI ≥ 25) was more frequent among ALL survivors. Obese ALL survivors showed adverse hormonal parameters and decreased testicular function, including lower serum testosterone and decreased serum inhibin B levels when compared to nonobese survivors. Altogether, 60% of obese survivors had received testicular irradiation compared with 29% of the nonobese survivors. The incidence of CRT (86 vs. 56%) was also higher among obese ALL survivors. The observed association with gonadotoxic testicular irradiation combined with CRT supports the idea that obesity is a consequence rather than an independent determinant of decreased gonadal function [38] in long-term survivors of ALL. Testicular irradiation that induces overt Leydig cell damage with the need of testosterone replacement therapy, especially when combined with CRT, can increase the risk of obesity among longterm survivors of childhood ALL.
The high prevalence of overweight (BMI ≥ 25) in the control group (51%) is in line with a previous longitudinal population-based follow-up study which shows that the prevalence of overweight among Finnish young men in the age group 19-39 years varies between 25 and 52%, and that of obesity (BMI ≥ 30) between 9 and 13% [39, 40] . According to these reports, the control subjects of the present study represent the general population of young men in Finland.
Our study suffers from some limitations. We conducted a cross-sectional analysis, and since the majority of survivors had received cranial irradiation, the effect of gonadotoxic antileukemia therapy on body composition could not be studied separately from the effects of CRT. The high proportion of survivors with prophylactic cranial and testicular irradiation reflects the early era of curative ALL therapy in the 70s and 80s, which differs from ALL therapy applied today. Evaluations were further compromised by the relatively small sample size and small number of obese survivors. Further, the patients and subjects were matched for age, sex, and ethnicity but not for BMI, which would have allowed us to better compare differences in body composition. Additionally, we do not have measures of body fat at ALL diagnosis in this survivor cohort.
In conclusion, our study shows that at young adulthood (mean age 29 years), long-term male ALL survivors have significantly higher percentages of body and trunk fat mass when compared with age-matched controls. Potential indicators of increased adiposity included increased leptin and low SHBG levels. The other serum testicular endocrine markers did not correlate with body adiposity. The increased adiposity in ALL survivors requires surveillance for possible other cardiovascular risk factors.
